DT&CRO Co. Ltd.
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2… Read more
DT&CRO Co. Ltd. (383930) - Net Assets
Latest net assets as of September 2025: ₩23.37 Billion KRW
Based on the latest financial reports, DT&CRO Co. Ltd. (383930) has net assets worth ₩23.37 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩87.30 Billion) and total liabilities (₩63.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩23.37 Billion |
| % of Total Assets | 26.77% |
| Annual Growth Rate | 16.76% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 84.31 |
DT&CRO Co. Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how DT&CRO Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DT&CRO Co. Ltd. (2021–2024)
The table below shows the annual net assets of DT&CRO Co. Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩28.67 Billion | -9.51% |
| 2023-12-31 | ₩31.68 Billion | -31.61% |
| 2022-12-31 | ₩46.32 Billion | +157.26% |
| 2021-12-31 | ₩18.01 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to DT&CRO Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1337929786000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.39 Billion | 22.27% |
| Other Components | ₩37.20 Billion | 129.76% |
| Total Equity | ₩28.67 Billion | 100.00% |
DT&CRO Co. Ltd. Competitors by Market Cap
The table below lists competitors of DT&CRO Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Provenance Gold Corp
OTCQB:PVGDF
|
$17.46 Million |
|
Seafire AB
ST:SEAF
|
$17.47 Million |
|
Primo Chemicals Limited
NSE:PRIMO
|
$17.47 Million |
|
Venu Holding Corporation
NYSE MKT:VENU
|
$17.47 Million |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
$17.45 Million |
|
GURU Organic Energy Corp
PINK:GUROF
|
$17.44 Million |
|
Diatreme Resources Ltd
AU:DRX
|
$17.43 Million |
|
Coeur d'Alene Bancorp Inc
PINK:CDAB
|
$17.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DT&CRO Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,678,923,790 to 28,667,402,810, a change of -3,011,520,980 (-9.5%).
- Net loss of 1,999,170,030 reduced equity.
- Share repurchases of 190,000,000 reduced equity.
- New share issuances of 190,000,000 increased equity.
- Other factors decreased equity by 1,012,350,950.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.00 Billion | -6.97% |
| Share Repurchases | ₩190.00 Million | -0.66% |
| Share Issuances | ₩190.00 Million | +0.66% |
| Other Changes | ₩-1.01 Billion | -3.53% |
| Total Change | ₩- | -9.51% |
Book Value vs Market Value Analysis
This analysis compares DT&CRO Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.29x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.01x to 1.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩1435.11 | ₩2885.00 | x |
| 2022-12-31 | ₩3667.36 | ₩2885.00 | x |
| 2023-12-31 | ₩2488.43 | ₩2885.00 | x |
| 2024-12-31 | ₩2244.81 | ₩2885.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DT&CRO Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.56%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.83x
- Recent ROE (-6.97%) is below the historical average (-6.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 24.03% | 13.21% | 1.00x | 1.83x | ₩2.53 Billion |
| 2022 | 11.35% | 11.94% | 0.68x | 1.39x | ₩623.44 Million |
| 2023 | -52.51% | -62.57% | 0.44x | 1.89x | ₩-19.80 Billion |
| 2024 | -6.97% | -5.56% | 0.44x | 2.83x | ₩-4.87 Billion |
Industry Comparison
This section compares DT&CRO Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DT&CRO Co. Ltd. (383930) | ₩23.37 Billion | 24.03% | 2.74x | $17.45 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |